salinomycin butyl ester analog

The salinomycin butyl ester analog is a semi-synthetic, small molecule research compound derived from salinomycin, a naturally occurring polyether ionophore antibiotic. It is created by modifying salinomycin at the C1 carboxylic acid position with a butyl ester group, with the goal of improving potency and selectivity against cancer stem cells (CSCs) relative to the parent compound. In preclinical studies, the butyl ester analog demonstrated significantly reduced colony-forming efficiency in triple-negative breast cancer cells (MDA-MB-231) and selectively depleted the CD44+/CD24-/low stem-cell-like subpopulation. Its mechanism of action involves potassium ionophore activity, which disrupts intracellular ion gradients and mitochondrial membrane potential, leading to DNA fragmentation and apoptotic cell death. No brand name, sponsoring company, or formal clinical development program has been identified for this specific compound; it remains a research-stage analog studied primarily in academic settings.

Other names

butyl salinomycinaten-butyl ester derivative of salinomycinsalinomycin butyl estersalinomycin n-butyl estersalinomycin n-butyl ester analog